deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01969708

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) (SCORE2)

Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.

Sponsor: Milton S. Hershey Medical Center

Conditions Central Retinal Vein Occlusion
Interventions aflibercept bevacizumab
Updated 17 times since 2017 Last updated: Jun 11, 2021 Started: Sep 30, 2014 Primary completion: Nov 30, 2016 Completion: Mar 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Central Retinal Vein Occlusion, this trial is completed. The trial is conducted by Milton S. Hershey Medical Center and has accumulated 17 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Sep 2020 · 15 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Sep 2021 — Dec 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Milton S. Hershey Medical Center
  • National Eye Institute (NEI)
  • The Emmes Company, LLC
  • University of Wisconsin, Madison
Data source: The Emmes Company, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Arlington, United States , Atlanta, United States , Augusta, United States , Austin, United States , Baltimore, United States , Charlotte, United States , Chevy Chase, United States , Chicago, United States , Cleveland, United States and 52 more locations